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APPENDIX
To see a table with the details of the 11 meta-analyses referred to in the text, please see the online version of this paper.
Drug-Eluting Stents for Saphenous Vein Graft Interventions
I read with interest the meta-analysis by Wiisanen et al. (1) regarding stents in saphenous vein graft interventions. I was surprised to see that the RRISC (Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent) trial is counted twice in the analysis of the randomized controlled trials. This study included 38 patients in the drug eluting stents (DES) and 37 in the bare-metal stents categories. The initial publication reports the 6-month outcome (2) , whereas the second publication reports long-term outcome of the same patients (3) . Counting these patients twice is obviously wrong. Unfortunately, this error leads to wrong conclusions such as, for example, the conclusion from the correct analysis of mortality in randomized controlled trials should be that DES are associated with increased mortality (17 deaths of 113 DES and 4 deaths of 89 bare-metal stents; p ϭ 0.027). This is in contradiction to the main conclusion of this manuscript that "DES use was associated with improved mortality." It is hard, if not impossible, to justify such a conclusion even if it is supported by nonrandomized cohort trials data when the randomized controlled trials data are contradictory. I believe the message to the readers from this manuscript is misleading, therefore, I believe the entire manuscript should be rewritten with the correct analysis and conclusions. 
Reply
We would like to thank the authors of the letters for their interest in our paper (1) . We agree that the RRISC (Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimuseluting stent) and DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) trials included the same patients (2, 3) . On the basis of the pre-specified criteria for the meta-analysis, we included all published trials on the use of drug-eluting stents (DES) versus bare-metal stents (BMS) in vein graft percutaneous coronary intervention (PCI). Because the included studies were weighted on the basis of study size, and because this particular study was small in size (only 75 patients), we did not anticipate any significant impact of this strategy on the overall conclusions. We analyzed the data with and without inclusion of the short-term RRISC data and found no significant differences in the conclusions. Drug-eluting stent use was associated with reduced mortality when early and delayed RRISC data were included (odds ratio [OR]: 0.72; 95% confidence interval [CI]: 0.58 to 0.89), and there was no significant difference when the early RRISC data were excluded (OR: 0.72; 95% CI: 0.58 to 0.89) (Fig.  1A) . Similarly, DES use-including early RRISC data-led to reduced target vessel revascularization (OR: 0.56; 95% CI: 0.40 to 0.77). Excluding these data, there was no significant change in the estimated benefit of DES on target vessel revascularization (OR: 0.58; 95% CI: 0.42 to 0.77) (Fig. 1B) . Identical conclusions were made when other adverse outcomes were analyzed with and without inclusion of early RRISC events.
Despite the statistically significant reduction in mortality associated with DES in our overall analysis, we clearly stated in the discussion that this is possibly caused by selection bias. We emphasized that this finding was primarily noted in the cohort trials and not in randomized trials, hence reinforcing the notion that it might have been driven by interventional operators selecting healthier patients to implant DES. We referenced the work by Shishehbor et al. (4), who made similar observations. Because of that concern, we opted not to state that mortality benefit in our final conclusions paragraph in the published paper (1) . The meta-analysis of the body of literature supports the fact that DES use in vein graft PCI is safe and not associated with increased risk of adverse events or mortality, despite the limitations and as noted in the conclusions paragraph. This remains our conclusion and that of others who performed similar meta-analyses (5-9).
We agree with the criticism of the multiplicity of metaanalyses performed on the same subject. We believe this is the effect of the publication and peer-review process as it works today. It is likely that-given the time it takes from writing the manuscript to submission, review, and response to editorial revisions-most of these manuscripts were making their way through the process at different journals at the same time, thus making it difficult to know that each of these papers was in press. As stated, this can be avoided with the creation of a central repository of systematic reviews and meta-analyses for authors to submit to as well as be aware of similar projects in development. Given the number of independent journals dedicated to cardiology and its subspecialties, this might not be an easy task.
